Joyce Hu
About Joyce Hu
Vice President, Head of Cancer Biology
Joyce Hu currently serves as Vice President, Head of Cancer Biology. In this role, she leads strategic initiatives in cancer research and oversees various projects aimed at advancing cancer diagnostics and therapeutics. Her responsibilities include managing research teams, developing experimental strategies, and ensuring the efficacy of research outcomes in the field of cancer biology.
Education and Expertise in Biomedical Sciences
Joyce Hu earned her Ph.D. in Biomedical Sciences with a focus on Immunology from the University of California, San Francisco. She also holds a B.S. in Music from the University of California, Berkeley. This unique educational background showcases her versatility and depth of knowledge in both the arts and sciences. She further honed her expertise through postdoctoral studies at the La Jolla Institute, where she studied the adaptive immune response to infection, cancer, and autoimmunity.
Research and Leadership at BioNTech US
Previously, Joyce Hu played a pivotal role at BioNTech US as Director and Head of Research in Gaithersburg, Maryland. In this position, she oversaw functional teams focused on various aspects of cancer research including biomarker discovery, TCR discovery, assay development, automation, sequencing, and bioinformatics. Her leadership facilitated significant advancements in the understanding and development of cancer treatments.
Postdoctoral Research at La Jolla Institute
Joyce Hu completed her postdoctoral studies at the La Jolla Institute, where she was involved in advanced research on the orchestration of the adaptive immune response to infection, cancer, and autoimmunity. Her work at the institute contributed to a deeper understanding of immune mechanisms and their applications in therapeutic contexts.
Development of T Cell-based Therapeutics
Throughout her career, Joyce Hu has been instrumental in developing personalized and off-the-shelf T cell-based therapeutics. She has worked with leading biotechnology companies such as Kite Pharma, Adaptive Biotechnologies, and Poseida Therapeutics. Her contributions have been crucial in advancing the field of immunotherapy and bringing innovative treatments to patients.